FGFR2 and gastric cancer: Interestingly, the authors note that although both nuclear and cytoplasmic expression of FGFR2 are considered as features of “FGFR2-enriched gastric cancer”, there are both clinical and IHC staining differences between nuclear and cytoplasmic FGFR2: while the authors consider that both nuclear and cytoplasmic overexpression of FGFR2 seem to be associated with a worse prognosis, with other authors highlighting nuclear overexpression as the worse of the two, antibodies targeting FGFR2 did not seem to attack nuclear FGFR2 [36].